Skip to main content
. Author manuscript; available in PMC: 2022 Sep 1.
Published in final edited form as: Patient Educ Couns. 2021 Feb 13;104(9):2240–2249. doi: 10.1016/j.pec.2021.02.024

Table 5.

Study 2: Percentages and means (95% confidence intervals [CI]) for dependent variables, by quantitative information conditions.

Quantitative information
Absent Present
N 452 450
% (CI) % (CI) P-value, OR
Gist recall/estimation
Item 1: False: “Xeravast eliminates the skin problems caused by plaque psoriasis.” 27.4 (23.3, 31.6) 33.3 (29.0, 37.7) 0.05, 1.33
Item 2: Agree: “Plaque psoriasis will improve but skin won’t be back to normal.” 34.5 (30.1, 38.9) 41.6 (37.0, 46.1) 0.03, 1.35
Item 3: True: “More than half of people with plaque psoriasis who take Xeravast will have some skin clearance in 2 months.” 90.3 (87.5, 93.0) 93.3 (91.0, 95.6) 0.09, 1.51
Verbatim recall/estimation
Item 1: 3 out of 4: “How many people with plaque psoriasis who take Xeravast will have some skin clearance in 2 months?” 37.8 (33.3, 42.3) 64.2 (59.8, 68.7) <0.001, 2.95
Item 2: 65%: “In most cases, Xeravast provided __% skin clearance in 2 months.” 5.1 (3.0, 7.1) 53.3 (48.7, 58.0) <0.001,21.59
Item 3: Higher than 65%: “In most cases, Xeravast provided __% skin clearance in 2 months.” 38.5 (34.0, 43.0) 21.6 (17.7, 25.4) <0.001,0.43
M (CI) M (CI) P-value, f
Perceived efficacy (1 = strongly disagree, 6 = strongly agree) 4.17 (4.07, 4.26) 4.14 (4.04, 4.24) 0.71, 0.01

Note. OR = odds ratio. Verbatim items 2 and 3 represent two different codes of the same questionnaire item: correct (65%) and overestimated (higher than 65%).